Frazier Life Sciences
30
95M
25
0.91
4
0.17
12
- Areas of investment
Investments analytics
Analytics
- Total investments
- 30
- Lead investments
- 4
- Exits
- 12
- Rounds per year
- 0.91
- Follow on index
- 0.17
- Investments by industry
- Biotechnology (23)
- Health Care (16)
- Therapeutics (11)
- Pharmaceutical (8)
- Biopharma (8) Show 10 more
- Investments by region
-
- United States (24)
- United Kingdom (3)
- Switzerland (1)
- Canada (1)
- Sweden (1)
- Peak activity year
- 2024
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 29M
- Group Appearance index
- 0.97
- Avg. company exit year
- 2
- Avg. multiplicator
- 0.07
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Enlaza Therapeutics | 12 Oct 2022 | Biotechnology, Health Care, Therapeutics, Biopharma | Seed | 61M | United States, California, La Jolla |
| Enlaza Therapeutics | 30 Apr 2024 | Biotechnology, Health Care, Therapeutics, Biopharma | Early Stage Venture | 100M | United States, California, La Jolla |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.